Mesothelioma Diagnosis and Prognosis, Are We Moving Beyond Histology and Performance Status Towards Circulating Biomarkers?

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2018 Jul 20

PMID 30023090

Citations 1

Authors

Oluf Dimitri Roe

Affiliations

Soon will be listed here.

Citing Articles

Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma.

Fontana V, Pistillo M, Vigani A, Canessa P, Berisso G, Giannoni U Oncol Lett. 2021; 21(2):128.

PMID: 33552249 PMC: 7798108. DOI: 10.3892/ol.2020.12389.

References

Zhuo Y, Lin L, Wei S, Zhang M . Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis. Medicine (Baltimore). 2016; 95(52):e5706. PMC: 5207566. DOI: 10.1097/MD.0000000000005706. View

Creaney J, Olsen N, Brims F, Dick I, Musk A, de Klerk N . Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev. 2010; 19(9):2238-46. DOI: 10.1158/1055-9965.EPI-10-0346. View

Robinson B, Creaney J, Lake R, Nowak A, William Musk A, de Klerk N . Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003; 362(9396):1612-6. DOI: 10.1016/S0140-6736(03)14794-0. View

Sun H, Vaynblat A, Pass H . Diagnosis and prognosis-review of biomarkers for mesothelioma. Ann Transl Med. 2017; 5(11):244. PMC: 5497115. DOI: 10.21037/atm.2017.06.60. View

Kirschner M, Pulford E, Hoda M, Rozsas A, Griggs K, Cheng Y . Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer. 2015; 113(6):963-9. PMC: 4578085. DOI: 10.1038/bjc.2015.286. View

Pass H, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M . hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010; 70(5):1916-24. PMC: 2831149. DOI: 10.1158/0008-5472.CAN-09-3993. View

Roe O, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P . Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer. 2008; 61(2):235-43. DOI: 10.1016/j.lungcan.2007.12.025. View

Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber D . Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer. 2017; 17(1):386. PMC: 5450182. DOI: 10.1186/s12885-017-3375-5. View

van Zandwijk N, Pavlakis N, Kao S, Linton A, Boyer M, Clarke S . Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017; 18(10):1386-1396. DOI: 10.1016/S1470-2045(17)30621-6. View

10.

Cao C, Tian D, Pataky K, Yan T . Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma. Lung Cancer. 2013; 81(3):319-327. DOI: 10.1016/j.lungcan.2013.04.024. View

11.

Pass H, Lott D, Lonardo F, Harbut M, Liu Z, Tang N . Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005; 353(15):1564-73. DOI: 10.1056/NEJMoa051185. View

12.

Napolitano A, Antoine D, Pellegrini L, Baumann F, Pagano I, Pastorino S . HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Clin Cancer Res. 2016; 22(12):3087-96. PMC: 4867109. DOI: 10.1158/1078-0432.CCR-15-1130. View

13.

Tsim S, Kelly C, Alexander L, McCormick C, Thomson F, Woodward R . Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study. BMJ Open. 2016; 6(11):e013324. PMC: 5168514. DOI: 10.1136/bmjopen-2016-013324. View

14.

Yamagishi T, Fujimoto N, Nishi H, Miyamoto Y, Hara N, Asano M . Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer. 2015; 90(1):111-7. DOI: 10.1016/j.lungcan.2015.07.014. View

15.

Meniawy T, Creaney J, Lake R, Nowak A . Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. Br J Cancer. 2013; 109(7):1813-20. PMC: 3790161. DOI: 10.1038/bjc.2013.504. View

16.

Bianchi M, Agresti A . HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev. 2005; 15(5):496-506. DOI: 10.1016/j.gde.2005.08.007. View

17.

Hassan R, Miller A, Sharon E, Thomas A, Reynolds J, Ling A . Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013; 5(208):208ra147. PMC: 6369691. DOI: 10.1126/scitranslmed.3006941. View

18.

Qian J, Qian Y, Wang J, Gu B, Pei D, He S . A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Des Devel Ther. 2016; 10:241-58. PMC: 4771399. DOI: 10.2147/DDDT.S88743. View

19.

Hollevoet K, Reitsma J, Creaney J, Grigoriu B, Robinson B, Scherpereel A . Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012; 30(13):1541-9. PMC: 3383122. DOI: 10.1200/JCO.2011.39.6671. View

20.

Roe O, Szulkin A, Anderssen E, Flatberg A, Sandeck H, Amundsen T . Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma. PLoS One. 2012; 7(8):e40521. PMC: 3414492. DOI: 10.1371/journal.pone.0040521. View